lamivudine

FDA Drug Profile — LAMIVUDINE, EPIVIR, lamivudine

lamivudine is listed in the FDA National Drug Code directory with 17 NDC codes, marketed under brand names including LAMIVUDINE, EPIVIR, lamivudine. Available dosage forms: tablet, film coated, powder, solution.

Drug details

Generic Name
lamivudine
Brand Names
LAMIVUDINE, EPIVIR, lamivudine
Application Number
ANDA091606
Sponsor
Apotex Corp.
NDC Codes
17
Dosage Forms
TABLET, FILM COATED, POWDER, SOLUTION
Routes
ORAL
Active Ingredients
LAMIVUDINE

Indications and Usage

1 INDICATIONS AND USAGE Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies ( 14.1 , 14.2 )]. The following points should be considered when initiating therapy with lamivudine tablets (HBV): • Due to high rates of resistance development in treated patients, initiation of treatment with lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • Lamivudine tablets (HBV) have not been evaluated in patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis delta virus. • Lamivudine tablets (HBV) have not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. Lamivudine tablets (HBV) are a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.